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Hypertrophic cardiomyopathy (HCM) is a heterogeneous cardiac disease based on autosomal genetic mutations of genes coding for proteins involving the sarcomeres and myofilament elements. [1] [2] [3] [4] The clinical consequences of these mutations are widely variable, ranging from patients remaining totally asymptomatic to the most dreaded outcome, sudden cardiac death (SCD) which accounts for over 50% of deaths in this population. 4 Despite considerable advances in our understanding of the genetic basis for this disease and its relation to the clinical course of patients with these mutations, 5 there remains considerable heterogeneity in the risk of adverse outcomes. This is especially relevant as a clinician tries to prevent sudden cardiac death for an individual patient while minimizing the burden of therapy. 6 The only established therapy to prevent sudden cardiac death in patients with HCM is the implantable cardioverter-defibrillator (ICD). [7] [8] [9] The generally accepted indications for prevention of SCD with an ICD in HCM are based on recognized risk factors, including a prior history of ventricular fibrillation or sustained ventricular tachycardia, maximum LV wall thickness C 30 mm, 10 SCD in a first degree relative with HCM, 11 unexplained syncope within the past 6 months, 12 nonsustained VT (especially if [ 150 bpm), 13 or an abnormal blood pressure response to exercise (failure to increase systolic pressure [ 20 mm Hg). 1, 2, 6, 7, 9, 11, 14 The risk of lethal arrhythmic events is higher for patients presenting with HCM in childhood, 5 those having Troponin I or T mutations, 5 and those with higher serum BNP concentrations. 15 The positive and negative predictive values of any one of these clinical risk factors to predict SCD have been relatively poor. 5, 6 In addition, for continuous variables such as LV wall thickness, the risk of SCD increases in a curvilinear manner, making a clear cut-off value that is ''safe'' all but impossible to establish. 16 Potential clinical features that increase the risk of SCD include younger age (\ 30 years), LV outflow tract obstruction, 17 a remote history of syncope, the presence of epicardial coronary artery disease, end-diastolic LV cavity dimension, 1 left atrial diameter, 12 and the presence of an LV aneurysm. 17 And yet, despite identification of these clinical features which have been well documented to increase the risk of SCD, even low-risk patients may experience this tragic outcome. 4, 6 The prevention of SCD is made more challenging by the fact that living with an ICD can be a significant burden to patients, including the risk of inappropriate shocks, lead malfunction, and requirement for pulse generator replacement. 8 Because of this, any technique that can reduce the need for ICD implantation in patients who are truly at low risk of SCD would be of high clinical value. 18 A welcome addition to risk assessment for patients with HCM has been the identification of late gadolinium enhancement (LGE) on cardiac MRI as an independent predictor of SCD. [19] [20] [21] [22] [23] [24] Compared with HCM patients without LGE, the adjusted SCD event risk increases continuously with the extent of LGE. For each 10% increase in the extent of LGE, the risk of SCD increased by a hazard ratio of 1.46. 21 An important observation has been that in patients with HCM who were considered to be at low risk for SCD by conventional clinical measures, the extent of LGE was able to identify patients who subsequently suffered SCD. 22 Among 429 patients with HCM without LGE, SCD occurred in 5 (1.2%). 22 Nevertheless, among the 37 patients with HCM suffering a potentially lethal ventricular arrhythmia, 11 (29.8%) had no LGE. 21 This calls for the question: Is there another way to predict SCD in patients with HCM who appear to be at low risk by conventional risk factors? The answer almost certainly involves accurate understanding of the pathologic substrate that produces ventricular arrhythmias in this disease. 3 This is especially likely when there is no significant myocardial scarring detectable by LGE on MRI. Considerable evidence has accumulated that ischemia and coagulative ischemic necrosis are important contributors to both myocardial fibrosis and the occurrence of SCD in HCM. [23] [24] [25] [26] [27] [28] [29] Autopsy studies have demonstrated intimal and medial thickening of intramyocardial arterioles which limit myocardial perfusion in HCM. 24, [30] [31] [32] [33] Along with increased myocardial oxygen demands of hypertrophied myocardium, blunted myocardial blood flow during stress produces ischemia. The increased interstitial fibrosis and reduced capillary density also contribute to ischemia in HCM. Increased levels of serum Troponin I in HCM are further evidence that ischemic injury is an important component of this disease.
Positron emission tomography (PET) with either O 15 -labeled water or N 13 -labeled ammonia is the most reliable method for imaging myocardial blood flow (MBF) in HCM. 34, 35 Measurements of MBF by PET at rest and during maximal vasodilation have demonstrated marked limitation of coronary flow reserve in patients with HCM in the absence of epicardial coronary artery disease, offering powerful evidence of microvascular dysfunction. 3 The relation of reduced MBF reserve and myocardial fibrosis using MRI has been well established in HCM. [33] [34] [35] Indeed, the identification of significantly reduced MBF reserve by PET has been shown to be a powerful predictor of subsequent mortality in HCM. 34 Bravo has summarized the role of PET for detection of myocardial ischemia in HCM. 36 The advantages of PET compared with SPECT include superior pharmacokinetic properties, higher spatial resolution of the reconstructed images, and more sensitive detection of radiotracer concentration. If patients with HCM can be identified as having a significant risk for SCD based on myocardial ischemia by PET imaging even in the absence of traditional risk factors, this tragic outcome may be further reduced. In addition, if PET imaging can be shown to identify a low risk of SCD in patients predicted to be at increased risk with standard risk factors, more patients could be spared the noxious effects of living with an ICD. However, before such an approach can be applied to HCM, prospective trials of PET imaging across the spectrum of this disease will be required. Towards this end there are issues that need to be addressed: (1) Is there an interaction between PET assessment of MBF and traditional risk factor for predicting SCD? (2) Can PET alone provide sufficient evidence for or against ICD implantation? (3) What is the optimal frequency that PET imaging should be performed in HCM patients without an ICD? (4) What is the best method for assessing epicardial coronary artery disease in HCM patients with abnormal perfusion by PET imaging? (5) Is there an interaction between specific genetic mutations underlying HCM and MBF assessed by PET imaging?
If these research questions can be answered, PET imaging may have a significant role to play in the management of patients with HCM, whereby patients who are not considered high risk for SCD by traditional clinical assessment might be identified early and protected by implantation of an ICD. In addition, if PET can be shown to attenuate the risk of SCD in the presence of standard risk factors, an ICD may be avoided for some patients with this disease. Both are useful goals.
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